Table 1.
Patient characteristics.
| Variables | Period A, N = 312 | Period B, N = 333 | Period C, N = 393 | Period D, N = 317 | p Value |
|---|---|---|---|---|---|
| Age – no. (%) | 0.008 | ||||
| ⩽65 years | 184 (59) | 179 (54) | 195 (50) | 146 (46) | |
| >65 years | 128 (41) | 154 (46) | 198 (50) | 171 (54) | |
| Sex – no. (%) | 0.549 | ||||
| Male | 204 (65) | 212 (64) | 267 (68) | 201 (63) | |
| Female | 108 (35) | 121 (36) | 126 (32) | 116 (37) | |
| ECOG PS – no. (%) | <0.001 | ||||
| 0 | 92 (29) | 112 (34) | 183 (47) | 168 (53) | |
| ⩾1 | 220 (71) | 221 (66) | 208 (53) | 149 (47) | |
| Prior gastrectomy – no. (%) | <0.001 | ||||
| Yes | 153 (49) | 131 (39) | 147 (38) | 206 (34) | |
| No | 159 (51) | 202 (61) | 241 (62) | 209 (66) | |
| Histology – no. (%) | 0.800 | ||||
| tub/pap | 92 (29) | 105 (32) | 118 (31) | 89 (28) | |
| por/sig/unknown | 220 (71) | 228 (68) | 266 (69) | 227 (72) | |
| HER2 status – no. (%) | 0.481 a | ||||
| Positive | 19 (6) | 28 (8) | 76 (19) | 62 (20) | |
| Negative | 83 (27) | 155 (47) | 289 (74) | 253 (80) | |
| Unknown | 210 (67) | 150 (45) | 28 (7) | 2 (1) | |
| Serum ALP – no. (%) | |||||
| ⩽ULN | 232 (75) | 250 (77) | 288 (74) | 237 (75) | |
| ⩾ULN | 76 (25) | 77 (23) | 101 (26) | 79 (25) | |
| Liver metastasis – no. (%) | |||||
| Yes | 92 (29) | 90 (27) | 99 (25) | 76 (24) | |
| No | 220 (71) | 243 (73) | 292 (75) | 241 (76) | |
| Peritoneal metastasis – no. (%) | |||||
| Yes | 181 (58) | 188 (55) | 226 (58) | 196 (62) | |
| No | 131 (42) | 145 (45) | 165 (42) | 121 (38) | |
| Number of metastatic site – no. (%) | |||||
| ⩽1 | 182 (58) | 200 (60) | 189 (48) | 168 (53) | |
| ⩾2 | 130 (42) | 133 (40) | 202 (52) | 149 (47) | |
a
Only cases with HER2 testing were analyzed.
ALP, alkaline phosphatase; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HER2, human epidermal growth factor receptor 2; ULN, upper limit of normal.